Filing Flows › West Pharmaceutical Services (WST) › Guidance history
West Pharmaceutical Services (WST) guidance history: what it guided and what it reported
West Pharmaceutical Services gave guidance in 12 earnings releases on file since Feb 15, 2024. Of 8 guided periods since reported, it met or beat its own guidance 8 times (100%). Revenue: 5 of 5, on average +2.2% against the guided midpoint. Its releases raised guidance 8 times and lowered it twice.
Revenue
Met or beat 5 of 5 periods (4 above, 1 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q3 2026 | $820M–$835M (Jul 23, 2026) | $874M | above the range | +5.7% |
| Q2 2026 | $830M–$850M (Apr 23, 2026) | $872M | above the range | +3.9% |
| FY2026 | $3.2B–$3.3B (Feb 12, 2026) → raised $3.3B–$3.4B (Apr 23, 2026) → raised $3.3B–$3.4B (Jul 23, 2026) → raised $3.4B–$3.4B (Oct 29, 2026) | — | to be reported | — |
| Q4 2025 | $790M–$800M (Oct 23, 2025) | $805M | above the range | +1.3% |
| FY2025 | $2.9B–$2.9B (Feb 13, 2025) → raised $2.9B–$3.0B (Apr 24, 2025) → raised $3.0B–$3.1B (Jul 24, 2025) → raised $3.1B–$3.1B (Oct 23, 2025) | $3.1B | above the range | +0.3% |
| FY2024 | $3.0B–$3.0B (Feb 15, 2024) → reaffirmed $3.0B–$3.0B (Apr 25, 2024) → lowered $2.9B–$2.9B (Jul 25, 2024) → reaffirmed $2.9B–$2.9B (Oct 24, 2024) | $2.9B | within the range | +0.1% |
Tax rate
Met or beat 3 of 3 periods (0 above, 0 within, 3 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2025 | 21.0% (Oct 23, 2025) | 20.1% | below the range | -0.9 pts |
| FY2025 | 22.0% (Feb 13, 2025) → reaffirmed 22.0% (Apr 24, 2025) → lowered 21.0% (Jul 24, 2025) | 19.8% | below the range | -1.2 pts |
| FY2024 | 22.5% (Feb 15, 2024) → reaffirmed 22.5% (Apr 25, 2024) → lowered 22.0% (Jul 25, 2024) | 17.9% | below the range | -4.1 pts |
| Q4 2024 | 22.0% (Oct 24, 2024) | — | — | — |
Capital expenditures
The GAAP figure from the filings is shown for each period reported; it is not judged against the guide, which may leave items out (one-off payments, acquisitions).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $250M–$275M (Feb 12, 2026) → lowered $215M–$220M (Oct 29, 2026) | — | to be reported | — |
| FY2025 | $275M (Feb 13, 2025) → reaffirmed $275M (Apr 24, 2025) → reaffirmed $275M (Jul 24, 2025) → reaffirmed $275M (Oct 23, 2025) | $286M (GAAP) | not judged | — |
| FY2024 | $350M (Feb 15, 2024) → reaffirmed $350M (Apr 25, 2024) → raised $375M (Jul 25, 2024) → reaffirmed $375M (Oct 24, 2024) | $377M (GAAP) | not judged | — |
GAAP EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $7.29 (Feb 12, 2026) → reaffirmed $7.29 (Apr 23, 2026) → reaffirmed $7.29 (Jul 23, 2026) → reaffirmed $7.29 (Oct 29, 2026) | — | to be reported | — |
| FY2025 | −$8.00 (Feb 13, 2025) → raised −$4.00 (Apr 24, 2025) → reaffirmed −$4.00 (Jul 24, 2025) → reaffirmed −$4.00 (Oct 23, 2025) | — | — | — |
| FY2024 | −$8.00 (Oct 24, 2024) | — | — | — |
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q3 2026 | $2.14–$2.24 (Jul 23, 2026) | — | — | — |
| Q2 2026 | $2.05–$2.12 (Apr 23, 2026) | — | — | — |
| Q1 2026 | $1.65–$1.70 (Feb 12, 2026) | — | — | — |
| FY2026 | $7.85–$8.20 (Feb 12, 2026) → raised $8.40–$8.75 (Apr 23, 2026) → raised $8.85–$9.05 (Jul 23, 2026) → raised $9.38–$9.48 (Oct 29, 2026) | — | to be reported | — |
| Q4 2025 | $1.81–$1.86 (Oct 23, 2025) | — | — | — |
| FY2025 | $6.00–$6.20 (Feb 13, 2025) → raised $6.15–$6.35 (Apr 24, 2025) → raised $6.65–$6.85 (Jul 24, 2025) → raised $7.06–$7.11 (Oct 23, 2025) | — | — | — |
| FY2024 | $7.50–$7.75 (Feb 15, 2024) → raised $7.63–$7.88 (Apr 25, 2024) → lowered $6.35–$6.65 (Jul 25, 2024) → raised $6.55–$6.75 (Oct 24, 2024) | — | — | — |
The latest quarter
West Pharmaceutical Services, Q3 2026: revenue $874M (+9% year over year), operating margin 30.6%, net earnings $214M, operating cash flow $190M. The chart follows the revenue to costs, profit and cash.
Questions
Does West Pharmaceutical Services beat its guidance?
West Pharmaceutical Services gave guidance in 12 earnings releases on file since Feb 15, 2024. Of 8 guided periods since reported, it met or beat its own guidance 8 times (100%). Revenue: 5 of 5, on average +2.2% against the guided midpoint.
How often does West Pharmaceutical Services raise guidance?
Its earnings releases raised guidance 8 times and lowered it twice since Feb 15, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.